Journal articleLancet Oncol2016

Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial.

DOI 10.1016/s1470-2045(16)00078-4 ↗ OpenAlex, retrieved 5 November 2026

Journal: Lancet Oncol
Published: 4 April 2016
Citations: 707
Type: Article

These are bibliographic fields. A study card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Trials 1

Builds on itFOLFIRINOX Plus PF-04136309 in Patients With Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma NCT01413022 ↗

Grants 4

Modulating innate immune cells in the tumor microenvironment of pancreas cancer to enhance anti-tumor immunity R01CA168863 ↗
The Impact of Macrophage Origin on the Pathogenesis and Treatment Resistance of Pancreatic Cancer R01CA177670 ↗
COMBINED TUMOR AND STROMAL TARGETING TO IMPROVE PANCREATIC CANCER RESPONSE TO IMMUNOTHERAPY R01CA203890 ↗
TARGETING CCR2 TO OVERCOME IMMUNOSUPPRESSION AND IMPROVE IMMUNOTHERAPY R21CA182701 ↗